Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription Articles published in Cancer Cell Retrieve available abstracts of 59 articles: HTML format

Single Articles

July 2026
1. IZUMI M, Kobayashi SS, Halmos B
   Targeting drug-tolerant persister cells: Let's bring on the TROPs!
   Cancer Cell. 2026;44:1333-1335.
   PubMed     Abstract available
   
   
   
2. LIU V, Sandor K, Yan PK, Miao Z, et al
   Clonal lineage tracing of innate immune cells in human cancer.
   Cancer Cell. 2026;44:1509-1521.
   PubMed     Abstract available
   
   
   June 2026
3. LIAO J, Yao W, Yu Y, Li A, et al
   Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer.
   Cancer Cell. 2026 Jun 18:S1535-6108(26)00265-5. doi: 10.1016/j.ccell.2026.
   PubMed     Abstract available
   
   
   
4. SUN H, Zhao S, Li J, Zhang L, et al
   Targeting internalization, resistance, and response: Insights from ICARUS-LUNG01.
   Cancer Cell. 2026;44:1113-1115.
   PubMed     Abstract available
   
   
   May 2026
5. DIJKSTRA KK, Vendramin R, Karagianni D, Witsen M, et al
   Subclonal immune evasion in non-small cell lung cancer.
   Cancer Cell. 2026 May 18:S1535-6108(26)00224-2. doi: 10.1016/j.ccell.2026.
   PubMed    
   
   
   
6. MA Y, Xue J, Gao F, Yang Y, et al
   JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1(G2032R) resistance mutation in NSCLC: The first-in-human phase 1 trial.
   Cancer Cell. 2026;44:983-994.
   PubMed     Abstract available
   
   
   April 2026
7. PLANCHARD D, Cozic N, Mosele MF, Corcos N, et al
   Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study.
   Cancer Cell. 2026 Apr 17:S1535-6108(26)00171-6. doi: 10.1016/j.ccell.2026.
   PubMed     Abstract available
   
   
   March 2026
8. MATEUS-TIQUE J, Lakshmi A, Singh B, Iyer R, et al
   Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth.
   Cancer Cell. 2026;44:534-550.
   PubMed     Abstract available
   
   
   
9. DUAN J, Sun Y, Wang Q, Xing L, et al
   HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial.
   Cancer Cell. 2026 Mar 5:S1535-6108(26)00104-2. doi: 10.1016/j.ccell.2026.
   PubMed     Abstract available
   
   
   
10. CAMPISI M, Osaki T, Dryg I, Stornante C, et al
    Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer.
    Cancer Cell. 2026 Mar 5:S1535-6108(26)00106-6. doi: 10.1016/j.ccell.2026.
    PubMed     Abstract available
    
    
    February 2026
11. PENG F, Sinjab A, Dai Y, Treekitkarnmongkol W, et al
    Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions.
    Cancer Cell. 2026;44:321-339.
    PubMed     Abstract available
    
    
    January 2026
12. HERBRICH S, Chaib M, Anandhan S, Andrewes SW, et al
    TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors.
    Cancer Cell. 2026;44:187-202.
    PubMed     Abstract available
    
    
    December 2025
13. SASAKI N, Homme M, Kitajima S
    Mapping the inflammatory origins of lung cancer.
    Cancer Cell. 2025 Dec 11:S1535-6108(25)00498-2. doi: 10.1016/j.ccell.2025.
    PubMed     Abstract available
    
    
    September 2025
14. SATPATHY S, Clark NM, Chen YJ, Hosseini N, et al
    Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures.
    Cancer Cell. 2025;43:1731-1757.
    PubMed     Abstract available
    
    
    
15. HE D, Wu Q, Tian P, Liu Y, et al
    Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps.
    Cancer Cell. 2025;43:1622-1636.
    PubMed     Abstract available
    
    
    July 2025
16. BENTON A, Liu J, Poussin MA, Lang Goldgewicht A, et al
    Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy.
    Cancer Cell. 2025;43:1365-1376.
    PubMed     Abstract available
    
    
    
17. GALAN-COBO A, Vokes NI, Qian Y, Molkentine D, et al
    KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer.
    Cancer Cell. 2025 Jul 5:S1535-6108(25)00261-2. doi: 10.1016/j.ccell.2025.
    PubMed     Abstract available
    
    
    
18. DIJKSTRA KK, Vendramin R, Karagianni D, Witsen M, et al
    Subclonal immune evasion in non-small cell lung cancer.
    Cancer Cell. 2025 Jul 1:S1535-6108(25)00262-4. doi: 10.1016/j.ccell.2025.
    PubMed     Abstract available
    
    
    June 2025
19. ZHU B, Chen P, Aminu M, Li JR, et al
    Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception.
    Cancer Cell. 2025;43:1125-1140.
    PubMed     Abstract available
    
    
    
20. BALASUBRAMANIAN A, Asselin-Labat ML
    Immune evolution in pre-invasive lung adenocarcinoma.
    Cancer Cell. 2025;43:1004-1006.
    PubMed     Abstract available
    
    
    
21. GURUNG S, Budden T, Mallela K, Jenkins B, et al
    Stromal lipid species dictate melanoma metastasis and tropism.
    Cancer Cell. 2025;43:1108-1124.
    PubMed     Abstract available
    
    
    May 2025
22. TENG M, Guo J, Xu X, Ci X, et al
    Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation.
    Cancer Cell. 2025;43:891-904.
    PubMed     Abstract available
    
    
    
23. LI Y, Oser MG
    A circular RNA in neuroendocrine carcinomas.
    Cancer Cell. 2025;43:812-814.
    PubMed     Abstract available
    
    
    February 2025
24. CHEN H, Deng C, Gao J, Wang J, et al
    Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer.
    Cancer Cell. 2025 Feb 14:S1535-6108(25)00030-3. doi: 10.1016/j.ccell.2025.
    PubMed     Abstract available
    
    
    
25. HENICK BS, Taylor AM, Nakagawa H, Wong KK, et al
    Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy.
    Cancer Cell. 2025;43:178-194.
    PubMed     Abstract available
    
    
    December 2024
26. HANGGI K, Li J, Gangadharan A, Liu X, et al
    Interleukin-1alpha release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity.
    Cancer Cell. 2024;42:2015-2031.
    PubMed     Abstract available
    
    
    October 2024
27. FU M, Zhao J, Zhang L, Sheng Z, et al
    Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade.
    Cancer Cell. 2024 Oct 9:S1535-6108(24)00360-X. doi: 10.1016/j.ccell.2024.
    PubMed     Abstract available
    
    
    September 2024
28. XU J, Wan R, Cai Y, Cai S, et al
    Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer.
    Cancer Cell. 2024;42:1598-1613.
    PubMed     Abstract available
    
    
    August 2024
29. MCRAE HM, Hargreaves DC
    Transcription factor dependencies identify BAF-dependent cancers.
    Cancer Cell. 2024;42:1326-1328.
    PubMed     Abstract available
    
    
    
30. HE T, Xiao L, Qiao Y, Klingbeil O, et al
    Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies.
    Cancer Cell. 2024;42:1336-1351.
    PubMed     Abstract available
    
    
    July 2024
31. DUPLAQUET L, So K, Ying AW, Pal Choudhuri S, et al
    Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer.
    Cancer Cell. 2024 Jul 17:S1535-6108(24)00237-X. doi: 10.1016/j.ccell.2024.
    PubMed     Abstract available
    
    
    June 2024
32. ZHOU Q, Pan Y, Yang X, Zhao Y, et al
    Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial.
    Cancer Cell. 2024 Jun 11:S1535-6108(24)00192-2. doi: 10.1016/j.ccell.2024.
    PubMed     Abstract available
    
    
    May 2024
33. MCGINNIS CS, Miao Z, Superville D, Yao W, et al
    The temporal progression of lung immune remodeling during breast cancer metastasis.
    Cancer Cell. 2024 May 24:S1535-6108(24)00167-3. doi: 10.1016/j.ccell.2024.
    PubMed     Abstract available
    
    
    
34. FINLAY JB, Ireland AS, Hawgood SB, Reyes T, et al
    Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer.
    Cancer Cell. 2024 May 20:S1535-6108(24)00164-8. doi: 10.1016/j.ccell.2024.
    PubMed     Abstract available
    
    
    
35. LIU SY, Feng WN, Wu YL
    Immunotherapy in resectable NSCLC: Answering the question or questioning the answer?
    Cancer Cell. 2024;42:727-731.
    PubMed     Abstract available
    
    
    March 2024
36. HU F, Lito P
    Insights into how adeno-squamous transition drives KRAS inhibitor resistance.
    Cancer Cell. 2024;42:330-332.
    PubMed     Abstract available
    
    
    
37. HE XY, Gao Y, Ng D, Michalopoulou E, et al
    Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment.
    Cancer Cell. 2024;42:474-486.
    PubMed     Abstract available
    
    
    February 2024
38. TONG X, Patel AS, Kim E, Li H, et al
    Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.
    Cancer Cell. 2024 Feb 20:S1535-6108(24)00036-9. doi: 10.1016/j.ccell.2024.
    PubMed     Abstract available
    
    
    
39. LIU NN, Yi CX, Wei LQ, Zhou JA, et al
    The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells.
    Cancer Cell. 2024;42:318-322.
    PubMed    
    
    
    
40. HUANG DD, Yang JC
    Re-inventing a better wheel? Serplulimab for squamous cell lung cancer.
    Cancer Cell. 2024;42:172-174.
    PubMed     Abstract available
    
    
    
41. BENGUIGUI M, Cooper TJ, Kalkar P, Schif-Zuck S, et al
    Interferon-stimulated neutrophils as a predictor of immunotherapy response.
    Cancer Cell. 2024;42:253-265.
    PubMed     Abstract available
    
    
    
42. NABET BY, Hamidi H, Lee MC, Banchereau R, et al
    Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.
    Cancer Cell. 2024 Feb 9:S1535-6108(24)00015-1. doi: 10.1016/j.ccell.2024.
    PubMed     Abstract available
    
    
    January 2024
43. HEEKE S, Gay CM, Estecio MR, Tran H, et al
    Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes.
    Cancer Cell. 2024 Jan 24:S1535-6108(24)00006-0. doi: 10.1016/j.ccell.2024.
    PubMed     Abstract available
    
    
    
44. MEMON D, Schoenfeld AJ, Ye D, Fromm G, et al
    Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer.
    Cancer Cell. 2024 Jan 9:S1535-6108(23)00441-5. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
45. CORDS L, Engler S, Haberecker M, Ruschoff JH, et al
    Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer.
    Cancer Cell. 2024 Jan 8:S1535-6108(23)00449-X. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    December 2023
46. ZHOU C, Hu Y, Arkania E, Kilickap S, et al
    A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004).
    Cancer Cell. 2023 Dec 21:S1535-6108(23)00432-4. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
47. DAYTON TL, Alcala N, Moonen L, den Hartigh L, et al
    Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites.
    Cancer Cell. 2023;41:2083-2099.
    PubMed     Abstract available
    
    
    
48. GERSTBERGER S, Ganesh K
    NEN in a dish: A patient-derived organoid biobank illuminates potential novel therapeutic opportunities for neuroendocrine neoplasms.
    Cancer Cell. 2023;41:2014-2016.
    PubMed     Abstract available
    
    
    
49. CHEN CC, Tran W, Song K, Sugimoto T, et al
    Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation.
    Cancer Cell. 2023;41:2066-2082.
    PubMed     Abstract available
    
    
    November 2023
50. JIAGGE E, Jin DX, Newberg JY, Perea-Chamblee T, et al
    Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers.
    Cancer Cell. 2023;41:1963-1971.
    PubMed     Abstract available
    
    
    
51. RAHAL Z, Kadara H
    Beyond bacteria: How the intratumor mycobiome modulates lung adenocarcinoma progression.
    Cancer Cell. 2023;41:1846-1848.
    PubMed     Abstract available
    
    
    October 2023
52. RODILLA AM, Valanparambil RM, Mack PC, Hsu CY, et al
    Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer.
    Cancer Cell. 2023 Oct 13:S1535-6108(23)00350-1. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
53. PAN Y, Zhang JT, Gao X, Chen ZY, et al
    Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients.
    Cancer Cell. 2023;41:1763-1773.
    PubMed     Abstract available
    
    
    
54. LI Z, Lu S
    Integrating minimal residual disease monitoring into clinical practice for NSCLC: Is the era upon us?
    Cancer Cell. 2023;41:1699-1701.
    PubMed     Abstract available
    
    
    September 2023
55. ZHU M, Kim J, Deng Q, Ricciuti B, et al
    Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden.
    Cancer Cell. 2023 Sep 26:S1535-6108(23)00322-7. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
56. LIU NN, Yi CX, Wei LQ, Zhou JA, et al
    The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells.
    Cancer Cell. 2023 Sep 19:S1535-6108(23)00288-X. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
57. TOPP BG, Channavazzala M, Mayawala K, De Alwis DP, et al
    Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression.
    Cancer Cell. 2023;41:1680-1688.
    PubMed     Abstract available
    
    
    
58. MEGYESFALVI Z, Heeke S, Drapkin BJ, Solta A, et al
    Unfolding the secrets of small cell lung cancer progression: Novel approaches and insights through rapid autopsies.
    Cancer Cell. 2023;41:1535-1540.
    PubMed     Abstract available
    
    
    
59. CHEN K, Yang F, Shen H, Wang C, et al
    Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer.
    Cancer Cell. 2023 Sep 1:S1535-6108(23)00286-6. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum